Ligand Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Los beneficios de Ligand Pharmaceuticals han disminuido a una tasa media anual de -61.7%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 0.1% al año. La rentabilidad financiera de Ligand Pharmaceuticals es de 7.7%, y sus márgenes netos son de 41%.

Información clave

-61.7%

Tasa de crecimiento de los beneficios

-57.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	-0.1%
Rentabilidad financiera	7.7%
Margen neto	41.0%
Próxima actualización de resultados	07 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17

Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year

Dec 31

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Dec 03

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Oct 11

Ligand's Ailing Remdesivir Cash Cow

Oct 11

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Ligand Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:LGND Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	131	54	53
30 Sep 23	154	21	68
30 Jun 23	180	41	68
31 Mar 23	204	51	69
31 Dec 22	196	-5	70
30 Sep 22	183	23	46
30 Jun 22	188	27	44
31 Mar 22	223	45	46
31 Dec 21	242	76	47
30 Sep 21	275	68	49
30 Jun 21	252	48	51
31 Mar 21	208	39	47
31 Dec 20	164	7	39
30 Sep 20	143	-16	45
30 Jun 20	126	-25	39
31 Mar 20	110	-61	40
31 Dec 19	120	629	42
30 Sep 19	153	594	43
30 Jun 19	174	677	43
31 Mar 19	239	764	41
31 Dec 18	251	143	38
30 Sep 18	242	179	34
30 Jun 18	230	120	32
31 Mar 18	168	53	29
31 Dec 17	141	13	29
30 Sep 17	129	16	28
30 Jun 17	117	9	27
31 Mar 17	109	-3	28
31 Dec 16	109	-2	28
30 Sep 16	92	7	27
30 Jun 16	88	205	25
31 Mar 16	87	235	25
31 Dec 15	72	230	25
30 Sep 15	74	231	24
30 Jun 15	71	33	25
31 Mar 15	63	11	23
31 Dec 14	65	12	23
30 Sep 14	56	7	21
30 Jun 14	54	8	19
31 Mar 14	53	10	19
31 Dec 13	49	9	18
30 Sep 13	48	10	18
30 Jun 13	41	7	17

Ingresos de calidad: LGND tiene un gran one-off gain de $47.6M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: LGND pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de LGND han disminuido en un 61.7% al año en los últimos 5 años.

Acelerando crecimiento: LGND ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: LGND ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (-6.8%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de LGND (7.7%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Ligand Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Announces Management Appointments

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 28%, revenue upgraded

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million.

Consensus EPS estimates increase by 73%

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Independent Chairman recently sold US$343k worth of stock

Independent Chairman notifies of intention to sell stock

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 41%

Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021)

Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Executive Director notifies of intention to sell stock

Executive Director exercised options to buy US$998k worth of stock.

Ligand Pharmaceuticals Incorporated Announces CEO Changes

Price target decreased to US$111

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%

Insufficient new directors

Chief Financial Officer recently sold US$128k worth of stock

Price target decreased to US$131

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022

Insufficient new directors

Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer

Ligand Pharmaceuticals Incorporated to Report Q3, 2022 Results on Nov 07, 2022

Price target decreased to US$149

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

CEO & Executive Director notifies of intention to sell stock

CEO & Executive Director recently sold US$180k worth of stock

Consensus estimates of losses per share improve by 14%

Consensus revenue estimates increase by 11%

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Full Year 2022

Ligand Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 08, 2022

Ligand Pharmaceuticals Incorporated Appoints Jason Haas to its Board of Directors

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Investor sentiment improved over the past week

Consensus forecasts updated

President & COO recently bought US$207k worth of stock

CEO & Executive Director exercised options to buy US$643k worth of stock.

Desglose de ingresos y gastos
Beta